| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1614166 | B | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | 34,209 | ALA1201862 | single protein format | PubChem BioAssays | ||
| 2. | ALA1614249 | B | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | Equus caballus | 42,059 | ALA1201862 | single protein format | PubChem BioAssays | |
| 3. | ALA1613914 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | Homo sapiens | 39,332 | ALA1201862 | assay format | PubChem BioAssays | |
| 4. | ALA1614291 | F | PUBCHEM_BIOASSAY: qHTS Validation Assay for Identification of Novel General Anesthetics. (Class of assay: confirmatory) | Equus caballus | 346 | ALA1201862 | assay format | PubChem BioAssays | |
| 5. | ALA1614427 | F | PUBCHEM_BIOASSAY: 14-3-3 protein interaction modulators Dose Response Confirmation. (Class of assay: confirmatory) [Related pubchem assays: 422 (Primary screen preceding this dose response confirmation assay.)] | Homo sapiens | 52 | ALA1201862 | assay format | PubChem BioAssays | |
| 6. | ALA1738442 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | Homo sapiens | 90,358 | ALA1201862 | assay format | PubChem BioAssays | |
| 7. | ALA1794483 | F | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | 114,923 | ALA1201862 | assay format | PubChem BioAssays | ||
| 8. | ALA2114817 | F | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | 17,358 | ALA1201862 | assay format | PubChem BioAssays | ||
| 9. | ALA2354221 | F | PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) | 172,532 | ALA1201862 | assay format | PubChem BioAssays | ||
| 10. | ALA2354287 | F | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | 39,968 | ALA1201862 | assay format | PubChem BioAssays | ||
| 11. | ALA3562077 | F | PubChem BioAssay. High Throughput Screening for Foot and Mouth Disease Virus Antivirals. (Class of assay: confirmatory) | 69,295 | ALA1201862 | assay format | PubChem BioAssays | ||
| 12. | ALA4303805 | F | Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging | Homo sapiens | 5,612 | ALA4303101 | organism-based format | SARS-CoV-2 Screening Data 2020-21 | |
| 13. | ALA4495582 | F | SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate | Severe acute respiratory syndrome coronavirus 2 | 7,212 | ALA4495564 | assay format | SARS-CoV-2 Screening Data 2020-21 | |
| 14. | ALA4513082 | F | Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging | Chlorocebus sabaeus | 7,212 | ALA4495565 | organism-based format | SARS-CoV-2 Screening Data 2020-21 |
The page will load shortly, Thanks for your patience!